Clinical efficacy of Shexiang Baoxin Wan combining trimetazidine in treatment of ischemic cardiomyopathy and heart failure in elderly patients：A Meta-analysis
LIN Xin-duo
WANG Jia-ning
TANG Jun-ming
YANG Jian-ye
ZHANG Lei
JIANG Feng-bo
ZHANG Xu-yang
Abstract：Objective To investigate the clinical efficacy of Shexiang Baoxin Wan combining trimetazidine in treatment of ischemic cardiomyopathy and heart failure in elderly patients.Methods The databases of Cochrane Library, PubMed, NTIS, PEDro, EMbase, CNKI, WanFang Database and VIP Database were retrieved with computer before Mar. 31, 2016 for collecting clinical randomized controlled trials (RCT) about Shexiang Baoxin Wan combining trimetazidine in treatment of ischemic cardiomyopathy and heart failure in elderly patients. All RCT were selected by 2 reviewers independently according to inclusion and exclusion criteria, and data was extracted, checked crossly and given methodological quality evaluation. The extracted data was given a Meta-analysis by using RevMan 5.2 software.Results The results of the Meta-analysis on 12 clinical RCT showed that left ventricular ejection fraction (LVEF) increased significantly (SMD=1.55, 95%CI: 0.85~2.25), left ventricular end-diastolic inner diameter (LVEDd) decreased significantly (SMD=-1.57, 95%CI: -1.91~ -1.22), 6-minute walk test (6MWT) increased significantly (WMD=56.98, 95%CI: 42.76~71.19) and clinical efficacy was significantly improved (RR=1.30, 95%CI: 1.23~1.38) in treatment group compared with control group (allP<0.05).Conclusion The current evidence indicates that LVEF, LVEDd, 6MWT and clinical efficacy are significantly improved in elderly patients with ischemic cardiomyopathy and heart failure treated with Shexiang Baoxin Wan combining trimetazidine.
Keywords：Shexiang Baoxin WanTrimetazidineSenile ischemic cardiomyopathyHeart failureMeta-analysis
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1162-1166 )